Comment on: Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials

J Chemother. 2017 Feb;29(1):62-64. doi: 10.1080/1120009X.2015.1113023. Epub 2016 Feb 6.

Authors

Andreas Sashegyi¹, Yawei Zhang², Yong Lin¹, Polina Binder², David Ferry²

Affiliations

¹ a Eli Lilly and Company , Indianapolis , IN , USA.
² b Eli Lilly and Company , Bridgewater , NJ , USA.

PMID: 27077927
DOI: 10.1080/1120009X.2015.1113023

No abstract available

Keywords: VEGFR/VEGF inhibitor; cancer; gastrointestinal perforation; meta-analysis; ramucirumab; risk.

MeSH terms

Antibodies, Monoclonal*
Antibodies, Monoclonal, Humanized
Humans
Neoplasms
Ramucirumab
Randomized Controlled Trials as Topic*
Risk

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized